AlphaMark Advisors’s Parnell Pharmaceuticals Holdings Ltd PARN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-400
Closed 599
2020
Q2
$0 Hold
400
﹤0.01% 658
2020
Q1
$0 Hold
400
﹤0.01% 646
2019
Q4
$0 Hold
400
﹤0.01% 538
2019
Q3
$0 Hold
400
﹤0.01% 542
2019
Q2
$0 Hold
400
﹤0.01% 547
2019
Q1
$0 Buy
+400
New ﹤0.01% 536
2018
Q4
Sell
-400
Closed 547
2018
Q3
$0 Hold
400
﹤0.01% 563
2018
Q2
$0 Buy
+400
New ﹤0.01% 561
2018
Q1
Sell
-400
Closed 549
2017
Q4
$0 Hold
400
﹤0.01% 539
2017
Q3
$0 Hold
400
﹤0.01% 574
2017
Q2
$0 Hold
400
﹤0.01% 573
2017
Q1
$0 Hold
400
﹤0.01% 537
2016
Q4
$0 Hold
400
﹤0.01% 489
2016
Q3
$1K Hold
400
﹤0.01% 338
2016
Q2
$1K Sell
400
-400
-50% -$735 ﹤0.01% 331
2016
Q1
$2K Hold
800
﹤0.01% 301
2015
Q4
$3K Buy
+800
New +$3.04K ﹤0.01% 282

AlphaMark Advisors's PARN Position: Q3 2020 in Review

AlphaMark Advisors sold out of Parnell Pharmaceuticals Holdings Ltd (PARN) in Q3 2020, closing a stake of 400 shares.

AlphaMark Advisors first reported a position in PARN in Q4 2015 and held it in 17 quarters. The position peaked at $3K in Q4 2015. 0 funds tracked by Wall St. Rank hold PARN as of Q3 2020.

  • AlphaMark Advisors reported no remaining Parnell Pharmaceuticals Holdings Ltd position as of Q3 2020 after selling out during the quarter.
  • AlphaMark Advisors sold 400 Parnell Pharmaceuticals Holdings Ltd shares in Q3 2020.
  • AlphaMark Advisors first reported a position in Parnell Pharmaceuticals Holdings Ltd in Q4 2015 and held it in 17 quarters.
  • AlphaMark Advisors's Parnell Pharmaceuticals Holdings Ltd position peaked at $3K in Q4 2015.
  • 0 funds tracked by Wall St. Rank held Parnell Pharmaceuticals Holdings Ltd as of Q3 2020.

Based on AlphaMark Advisors's 13F filing for Q3 2020, filed 6 Nov 2020.